Trial Profile
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Rociletinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Clovis Oncology [CEASED]
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 05 May 2016 According to Clovis Oncology media release, company was notified that it could anticipate receiving a Complete Response Letter (CRL) for the rociletinib NDA on or before the PDUFA date of June 28, 2016 but the FDA issued a CRL stating that the application is not ready for approval. Hence, company has terminated enrollment in all ongoing studies.
- 05 May 2016 Status changed from recruiting to discontinued, as reported by Clovis Oncology media release.